US Bancorp DE Buys 3,921 Shares of Replimune Group, Inc. $REPL

US Bancorp DE boosted its holdings in Replimune Group, Inc. (NASDAQ:REPL) by 582.6% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 4,594 shares of the company’s stock after purchasing an additional 3,921 shares during the quarter. US Bancorp DE’s holdings in Replimune Group were worth $45,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in REPL. Sterling Capital Management LLC increased its holdings in shares of Replimune Group by 364.5% during the fourth quarter. Sterling Capital Management LLC now owns 2,109 shares of the company’s stock valued at $26,000 after acquiring an additional 1,655 shares in the last quarter. Tower Research Capital LLC TRC boosted its position in Replimune Group by 696.7% in the fourth quarter. Tower Research Capital LLC TRC now owns 6,772 shares of the company’s stock worth $82,000 after purchasing an additional 5,922 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Replimune Group by 106.2% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,410 shares of the company’s stock worth $111,000 after purchasing an additional 5,876 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Replimune Group in the fourth quarter valued at $117,000. Finally, Quantinno Capital Management LP bought a new stake in shares of Replimune Group in the fourth quarter valued at $127,000. 92.53% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

REPL has been the topic of a number of analyst reports. Leerink Partnrs lowered Replimune Group from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 22nd. HC Wainwright lowered Replimune Group from a “buy” rating to a “neutral” rating in a research note on Wednesday, July 23rd. JPMorgan Chase & Co. restated a “neutral” rating and issued a $9.00 target price (down from $19.00) on shares of Replimune Group in a research note on Tuesday, July 22nd. Wedbush restated a “neutral” rating and issued a $4.00 target price (down from $19.00) on shares of Replimune Group in a research note on Tuesday, July 22nd. Finally, Piper Sandler lowered Replimune Group from an “overweight” rating to a “neutral” rating and set a $3.00 target price on the stock. in a research note on Tuesday, July 22nd. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $7.67.

Insiders Place Their Bets

In related news, CFO Emily Luisa Hill sold 9,154 shares of the stock in a transaction dated Friday, August 15th. The stock was sold at an average price of $5.37, for a total transaction of $49,156.98. Following the completion of the sale, the chief financial officer directly owned 134,368 shares in the company, valued at $721,556.16. This represents a 6.38% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. 5.20% of the stock is owned by corporate insiders.

Replimune Group Trading Down 0.9%

Shares of REPL stock opened at $5.28 on Wednesday. The stock has a market capitalization of $412.16 million, a PE ratio of -1.63 and a beta of 0.67. Replimune Group, Inc. has a 1-year low of $2.68 and a 1-year high of $17.00. The business has a 50-day moving average of $8.04 and a 200 day moving average of $9.46. The company has a debt-to-equity ratio of 0.21, a current ratio of 6.94 and a quick ratio of 6.94.

Replimune Group (NASDAQ:REPL) last issued its earnings results on Thursday, August 7th. The company reported ($0.95) earnings per share for the quarter, missing the consensus estimate of ($0.83) by ($0.12). As a group, sell-side analysts anticipate that Replimune Group, Inc. will post -2.97 earnings per share for the current year.

Replimune Group Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.